Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1972 1
1978 2
1979 7
1980 7
1981 13
1982 13
1983 6
1984 19
1985 13
1986 17
1987 23
1988 31
1989 14
1990 24
1991 25
1992 26
1993 34
1994 29
1995 15
1996 18
1997 11
1998 16
1999 15
2000 16
2001 23
2002 19
2003 27
2004 32
2005 22
2006 16
2007 18
2008 14
2009 18
2010 21
2011 23
2012 21
2013 36
2014 47
2015 56
2016 57
2017 56
2018 49
2019 40
2020 53
2021 47
2022 48
2023 53
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

1,138 results

Results by year

Filters applied: . Clear all
Page 1
Familial hypercholesterolemia.
Bouhairie VE, Goldberg AC. Bouhairie VE, et al. Cardiol Clin. 2015 May;33(2):169-79. doi: 10.1016/j.ccl.2015.01.001. Cardiol Clin. 2015. PMID: 25939291 Free PMC article. Review.
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia.
McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. McGowan MP, et al. J Am Heart Assoc. 2019 Dec 17;8(24):e013225. doi: 10.1161/JAHA.119.013225. Epub 2019 Dec 16. J Am Heart Assoc. 2019. PMID: 31838973 Free PMC article. Review. No abstract available.
Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L, Kayikcioglu M. Tokgozoglu L, et al. Curr Cardiol Rep. 2021 Sep 4;23(10):151. doi: 10.1007/s11886-021-01565-5. Curr Cardiol Rep. 2021. PMID: 34480646 Review.
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and the LDL-receptor adaptor protein 1 (LDLRAP1) genes cause FH. ...
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase su …
A Comprehensive Review of PCSK9 Inhibitors.
Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M. Coppinger C, et al. J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221100107. doi: 10.1177/10742484221100107. J Cardiovasc Pharmacol Ther. 2022. PMID: 35593194 Free article. Review.
Ezetimibe reduces LDL-C by 15%-20% when combined with statin.(2,3) Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been found to achieve profound reductions in LDL-C (54%-74%) when added to statins. ...
Ezetimibe reduces LDL-C by 15%-20% when combined with statin.(2,3) Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have …
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease.
Benito-Vicente A, Uribe KB, Jebari S, Galicia-Garcia U, Ostolaza H, Martin C. Benito-Vicente A, et al. Int J Mol Sci. 2018 Nov 1;19(11):3426. doi: 10.3390/ijms19113426. Int J Mol Sci. 2018. PMID: 30388787 Free PMC article. Review.
Malfunctioning of cholesterol metabolism is caused by multiple hereditary diseases, including Familial Hypercholesterolemia, Sitosterolemia Type C and Niemann-Pick Type C1. Of these, familial hypercholesterolemia (FH) is a common inherited autosomal co-dominant diso …
Malfunctioning of cholesterol metabolism is caused by multiple hereditary diseases, including Familial Hypercholesterolemia, Sitosterolemia …
Familial hypercholesterolaemia.
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Defesche JC, et al. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. Nat Rev Dis Primers. 2017. PMID: 29219151 Review.
Clinical severity depends on the nature of the gene that harbours the causative mutation, among other factors, and is further modulated by the type of mutation. Lifelong LDL cholesterol-lowering treatment substantially improves CVD-free survival and longevity. ...
Clinical severity depends on the nature of the gene that harbours the causative mutation, among other factors, and is further modulated by t …
1,138 results